NeuroSense Therapeutics Ltd. (NRSN): Financial results for H1 2026
NeuroSense Therapeutics Ltd. (NRSN) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 NeuroSense Provides Business Update and Progress for the First Half of 2026 CAMBRIDGE, Mass., September 25, 2026 -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense” or the “Company”), a late-stage clinical biotechnology company focused on developing disease-
How this was made
The 30-second read
Why it matters
The earnings release provides fresh financials and clinical updates, offering traders new data to price the stock.
Market read
Primary earnings disclosure with material trial data; relevant for biotech investors.
What to watch
Potential upcoming NDS filing in Canada could unlock financing and partnership opportunities.
NeuroSense reported lower H1 2026 operating expenses and advanced PrimeC regulatory planning, while ending the period with $231 thousand of cash and cash equivalent and continuing to pursue financing and strategic alternatives.
Operating expenses and net loss declined from H1 2025, and PrimeC regulatory and clinical milestones progressed, but the Company reported $231 thousand of cash and cash equivalent, a total shareholders’ deficit of $(2,103) thousand, and stated that it continues to pursue financing opportunities and strategic alternatives.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expenses, six months ended June 30, 2026other | $2.10M | – | decrease of $401 thousand, or 16% |
| General and administrative expenses, six months ended June 30, 2026other | $1.34M | – | decrease of $844 thousand, or 38.6% |
| Operating expenses, six months ended June 30, 2026other | $3.4M | – | – |
| Operating loss, six months ended June 30, 2026other | −$3.45M | – | – |
| Financing expenses, net, six months ended June 30, 2026other | −$116K | – | – |
| Net loss and comprehensive loss, six months ended June 30, 2026other | −$3.56M | – | – |
| Basic and diluted net loss per share, six months ended June 30, 2026other | $(2.1) | – | – |
| Weighted average number of shares outstanding used in computing basic and diluted net loss per share, six months ended June 30, 2026other | 1,731,255 shares | – | – |
| Cash and cash equivalent as of June 30, 2026other | $231K | – | – |
| Other receivables as of June 30, 2026other | $540K | – | – |
| Restricted deposit, current, as of June 30, 2026other | $73K | – | – |
| Total current assets as of June 30, 2026other | $844K | – | – |
| Property, plant and equipment, net, as of June 30, 2026other | $52K | – | – |
| Total assets as of June 30, 2026other | $896K | – | – |
| Trade payables as of June 30, 2026other | $729K | – | – |
| Other current liabilities as of June 30, 2026other | $2.27M | – | – |
| Total current liabilities as of June 30, 2026other | $3.00M | – | – |
| Total liabilities as of June 30, 2026other | $3.00M | – | – |
| Share premium and capital reserve as of June 30, 2026other | $49.24M | – | – |
| Accumulated deficit as of June 30, 2026other | −$51.35M | – | – |
| Total shareholders’ deficit as of June 30, 2026other | −$2.10M | – | – |
| Issued and outstanding shares as of June 30, 2026other | 1,836,154 shares | – | – |
Remainder of 2026 outlook
- NoteTargeting December 2026 NDS filing in Canada
- NoteThe Company is now targeting an NDS filing in early December 2026.
- NoteThe Company plans to discuss with the FDA whether the existing data may support full approval or, alternatively, an Accelerated Approval pathway.
What drove it
- Research and development expense decreased mainly due to a decrease in subcontractors and consultants, partly offset by an increase in share-based payment expense.
- General and administrative expense decreased mainly due to a decrease in professional services.
- PARADIGM achieved its primary endpoint in June 2026, demonstrating a statistically significant treatment-associated reduction in extracellular vesicle-associated TDP-43 compared with placebo.
- The Company completed the Pre-NDS process with Health Canada, and final meeting minutes reflected alignment on the planned content and structure of the ALS submission.
- The Company is pursuing an optimized U.S. development strategy that includes AI-enabled characterization, a planned active-comparator study against edaravone, and evaluation of a smaller and shorter pivotal PARAGON design.
Concerns
- The Company reported $231 thousand of cash and cash equivalent as of June 30, 2026.
- The Company reported a net loss and comprehensive loss of $(3,563) thousand for the six months ended June 30, 2026.
- The Company reported total shareholders’ deficit of $(2,103) thousand as of June 30, 2026.
- The Company continues to pursue financing opportunities, including potential non-dilutive funding sources, and is evaluating strategic alternatives.
- Any revised pivotal design or regulatory pathway for PrimeC remains subject to FDA alignment.
- The filing identifies risks relating to the ability to obtain additional financing, regulatory submissions and approvals, clinical-trial timing and results, Nasdaq listing compliance, and the availability of strategic, partnering or financing opportunities.
What to watch
- Submission of the planned Canadian NDS for PrimeC in ALS, targeted for December 2026.
- FDA discussions on whether existing data may support full approval or an Accelerated Approval pathway.
- The proposed active-comparator study against edaravone and potential smaller and shorter pivotal PARAGON design.
- Financing, potential non-dilutive funding, partnerships, strategic alternatives and potential business or corporate transactions.
- Progress of PrimeC in ALS and the Alzheimer’s RoAD proof-of-concept program.
Balance sheet and cash flow
- Cash and cash equivalent was $231 thousand as of June 30, 2026, compared with $166 thousand as of December 31, 2025.
- Total assets were $896 thousand as of June 30, 2026, compared with $1,028 thousand as of December 31, 2025.
- Total liabilities were $2,999 thousand as of June 30, 2026, compared with $2,588 thousand as of December 31, 2025.
- Total shareholders’ deficit was $(2,103) thousand as of June 30, 2026, compared with $(1,560) thousand as of December 31, 2025.
- Issuance of shares, net was 120,483 shares and $2,066 thousand during the six months ended June 30, 2026.
- Share-based compensation was 72,998 shares and $954 thousand during the six months ended June 30, 2026.
Analysis
NeuroSense reported a lower H1 2026 operating-cost base versus H1 2025. Research and development expenses were $2,102 thousand, down $401 thousand, or 16%, while general and administrative expenses were $1,345 thousand, down $844 thousand, or 38.6%. The Company attributed the R&D reduction mainly to lower subcontractor and consultant costs, partly offset by higher share-based payment expense, and attributed the G&A reduction mainly to lower professional-services expense. Operating expenses were $3.4 million versus $4.7 million in the prior-year period, while net loss and comprehensive loss was $(3,563) thousand versus $(4,709) thousand.
The release is centered on clinical and regulatory progress rather than commercial activity. NeuroSense stated that PARADIGM achieved its primary endpoint in June 2026, showing a statistically significant treatment-associated reduction in extracellular vesicle-associated TDP-43 compared with placebo. The Company also cited publication of Phase 2b PARADIGM results in JAMA Neurology in March 2026 and reported long-term follow-up showing a statistically significant 65% reduction in the risk of death and estimated median survival of 36.3 months for participants treated continuously with PrimeC, compared with 21.4 months for participants initially assigned to placebo before crossing over to PrimeC.
The near-term regulatory milestone is a Canadian NDS for PrimeC in ALS, targeted for December 2026, with the release also referring to an early December 2026 target. NeuroSense said it completed the Pre-NDS process and that final Health Canada meeting minutes reflected alignment on the planned content and structure of the submission. In the United States, management is working toward an optimized development strategy involving AI-enabled formulation characterization, a planned active-comparator study against edaravone and evaluation of a smaller and shorter pivotal PARAGON design. The Company plans to discuss full-approval and Accelerated Approval possibilities with the FDA, but stated that any revised pivotal design or regulatory pathway remains subject to FDA alignment.
Liquidity and capitalization remain central issues. Cash and cash equivalent was $231 thousand as of June 30, 2026, while total current liabilities were $2,999 thousand and total shareholders’ deficit was $(2,103) thousand. The Company recorded $2,066 thousand from issuance of shares, net during the six-month period and reported 1,836,154 issued and outstanding shares at June 30, 2026. Management explicitly said it continues to pursue financing opportunities, including potential non-dilutive sources, and to evaluate strategic alternatives and potential transactions intended to provide resources for PrimeC development.
The key items for the remainder of 2026 are the timing and completion of the Canadian NDS, the outcome of FDA discussions on PrimeC's U.S. pathway and PARAGON design, and financing or strategic actions. The release does not provide revenue, commercial metrics, cash-flow metrics, formal financial guidance, or a disclosed debt balance.
Management, verbatim
Our focus remains on advancing PrimeC toward the next stage of development and, ultimately, toward patients. We are working diligently to move our development plans forward in a capital-efficient manner, while pursuing the regulatory, clinical, financing and strategic opportunities available to us. Looking ahead, our priorities include advancing our regulatory pathway in Canada, preparing for the next clinical stage of PrimeC in ALS, and pursuing the funding, partnerships and strategic alternatives that can support the continued development of the program. We remain fully committed to doing everything we can to realize PrimeC’s potential to address the significant unmet need in ALS.
Alon Ben-Noon, Chief Executive Officer of NeuroSense
Not in the filing
stated, not guessed- Revenue
- Segment revenue and segment comparisons
- Gross profit and gross margin
- Tax rate
- Operating cash flow
- Free cash flow
- Debt balance
- Current lease liability amount
- Capital returns, including dividends and share repurchases
- Formal revenue guidance
- Formal gross-margin guidance
- Formal operating-expense guidance
- Formal tax-rate guidance
- Prior-quarter comparisons for reported operating metrics
- Financial reporting framework, such as IFRS or local GAAP
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
NeuroSense Therapeutics is a late‑stage biotech focused on ALS, reporting H1 2026 results via a Form 6‑K filing.
Ticker impact
SEC Form 6-K provides NeuroSense Therapeutics' H1 2026 earnings, including R&D expense decline and Phase 2b PARADIGM trial results.
Potential short-term downside pressure from loss, offset by upside if investors value trial data.
Earnings release is primary source; trial data is material for biotech valuation.
Market effects
Positive ALS trial data may lift peer biotech sector.
US and Canadian biotech investors may adjust exposure.
Limited to biotech niche; no broad market effect.
Counterpoint
Losses and cash burn could outweigh trial optimism, prompting short positions.
Key entities
- CompanyNeuroSense Therapeutics Ltd.
NASDAQ‑listed biotech reporting H1 2026 results.
- ExecutiveAlon Ben-Noon
CEO of NeuroSense, quoted on development plans.
